Business NewsPR NewsWire • Genome Editing and Cellular Therapies Show Promise for Treating Blood Disorders, Cancers

Genome Editing and Cellular Therapies Show Promise for Treating Blood Disorders, Cancers

Genome Editing and Cellular Therapies Show Promise for Treating Blood Disorders, Cancers

WASHINGTON, Dec. 5, 2020 /PRNewswire/ -- Three studies being presented during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition report promising results in the use of cutting-edge genome editing and cellular therapies for hard-to-treat blood disorders and cancers....

View More : https://www.prnewswire.com:443/news-releases/genome-editing-and-cellular-therapies-show-promise-for-treating-blood-disor...
Releted News by prnewswire
Novartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas
Lancement de la première étude d'immunothérapie cellulaire UniCAR sur les tumeurs solides avancées
Sysmex Inostics Presents Data at the American Society of Hematology Annual Meeting Demonstrating Exquisite Sensitivity of SafeSEQ NGS Technology for Detection of Measurable Residual Disease in Acute Myeloid Leukemia
Genome Editing and Cellular Therapies Show Promise for Treating Blood Disorders, Cancers
AbbVie Presents Extended Follow-Up Data for Fixed Duration Treatment VENCLEXTA®/VENCLYXTO® (venetoclax) in Chronic Lymphocytic Leukemia (CLL)
Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia
Pharma Targeting announces team expansion to cope with surge in virtual business units